Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer
Mené sur 886 patients atteints d'un cancer urothélial de stade localement avancé ou métastatique (durée médiane de suivi : 17,2 mois), cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité d'une chimiothérapie à base de sels de platine et d'un traitement combinant enfortumab védotin et pembrolizumab
For several decades, platinum-based chemotherapy has been the standard first-line option for patients with advanced inoperable or metastatic (or both) urothelial carcinoma. This paradigm, in which platinum-based chemotherapy was considered to be the only effective first-line chemotherapy, was implemented in the 1980s1 and remained unchanged even after immune checkpoint inhibitors were introduced in recent years as part of the treatment regimen for metastatic urothelial carcinoma. Treatment advances were made by replacing older treatments with less toxic combinations (e.g., gemcitabine and cisplatin2) or by replacing cisplatin with carboplatin in patients who were ineligible to receive cisplatin3 rather than by improving treatment (...)